2022年：心血管疾病之年——起始联合降脂治疗之年 - Suppr

2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.

作者信息

Banach Maciej, Reiner Zeljko, Cicero Arrigo F G, Sabouret Pierre, Viigimaa Margus, Sahebkar Amirhossein, Postadzhiyan Arman, Gaita Dan, Pella Daniel, Penson Peter E

机构信息

Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland.

Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.

出版信息

Arch Med Sci. 2022 Nov 7;18(6):1429-1434. doi: 10.5114/aoms/156147. eCollection 2022.

DOI:10.5114/aoms/156147

PMID:36457968

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9710261/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dccf/9710261/e5ebe230ec46/AMS-18-6-156147-g001.jpg

相似文献

2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.

Arch Med Sci. 2022 Nov 7;18(6):1429-1434. doi: 10.5114/aoms/156147. eCollection 2022.

Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.

Eur J Prev Cardiol. 2023 Nov 30;30(17):1856-1864. doi: 10.1093/eurjpc/zwad193.

A Clinical Guide to Combination Lipid-Lowering Therapy.

Curr Atheroscler Rep. 2018 Mar 7;20(4):19. doi: 10.1007/s11883-018-0721-2.

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data.

J Am Heart Assoc. 2023 Sep 19;12(18):e030414. doi: 10.1161/JAHA.123.030414. Epub 2023 Sep 6.

The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering.

Circulation. 2020 Sep;142(9):827-837. doi: 10.1161/CIRCULATIONAHA.120.045851. Epub 2020 Jul 23.

Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.

J Am Coll Cardiol. 2023 Aug 1;82(5):401-410. doi: 10.1016/j.jacc.2023.05.042.

Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.

Chest. 2023 Dec;164(6):1518-1530. doi: 10.1016/j.chest.2023.06.023. Epub 2023 Jun 24.

Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.

Ann Vasc Surg. 2020 Nov;69:197-205. doi: 10.1016/j.avsg.2020.06.003. Epub 2020 Jun 15.

Effects of intensive lipid lowering compared with moderate-intensity lipid lowering on coronary atherosclerotic plaque phenotype and major adverse cardiovascular events in adults with low to intermediate 10-year ASCVD risk (ILLUMINATION study): protocol for a multicentre, open-label, blinded-endpoint, randomised controlled trial.

BMJ Open. 2023 Jun 5;13(6):e070832. doi: 10.1136/bmjopen-2022-070832.

Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.

BMC Cardiovasc Disord. 2020 Jul 13;20(1):334. doi: 10.1186/s12872-020-01567-1.

引用本文的文献

A natural small molecule isoginkgetin alleviates hypercholesterolemia and atherosclerosis by targeting ACLY.

Theranostics. 2025 Mar 18;15(10):4325-4344. doi: 10.7150/thno.105782. eCollection 2025.

Assessing LDL-C Levels and Lipid-Modifying Therapies in a Real-World Cohort of Patients with Atherosclerotic Cardiovascular Disease: The REALITY Study.

J Clin Med. 2025 Mar 28;14(7):2340. doi: 10.3390/jcm14072340.

Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment.

Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):367-379. doi: 10.1093/ehjcvp/pvaf007.

2024 consensus document of the Italian Society of Arterial Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC): update on LDL cholesterol lowering in patients with arterial hypertension.

High Blood Press Cardiovasc Prev. 2025 Mar;32(2):151-163. doi: 10.1007/s40292-024-00700-x. Epub 2025 Feb 25.

Impact of surrogates for insulin resistance on mortality and life expectancy in primary care: a nationwide cross-sectional study with registry linkage (LIPIDOGRAM2015).

Lancet Reg Health Eur. 2024 Dec 12;49:101182. doi: 10.1016/j.lanepe.2024.101182. eCollection 2025 Feb.

Looking Back, Leaning Forward-A Contemporary Overview of Acute Coronary Syndrome.

J Clin Med. 2024 Dec 2;13(23):7331. doi: 10.3390/jcm13237331.

Lipoprotein(a) and other risk factors in dyslipidemic patients with and without heart failure.

Arch Med Sci. 2024 Oct 16;20(5):1705-1709. doi: 10.5114/aoms/194684. eCollection 2024.

Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and methodology.

Arch Med Sci. 2024 Aug 8;20(5):1452-1460. doi: 10.5114/aoms/192147. eCollection 2024.

A Nation-Wide Evaluation of Suboptimal Lipid-Lowering Treatment Patterns Among Patients Undergoing Intervention for Acute Coronary Syndrome in Hungary.

J Clin Med. 2024 Oct 31;13(21):6562. doi: 10.3390/jcm13216562.

2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP).

Drugs. 2024 Dec;84(12):1541-1577. doi: 10.1007/s40265-024-02105-5. Epub 2024 Nov 4.

本文引用的文献

Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data.

J Am Heart Assoc. 2023 Sep 19;12(18):e030414. doi: 10.1161/JAHA.123.030414. Epub 2023 Sep 6.

Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program.

Kardiol Pol. 2023;81(4):359-365. doi: 10.33963/KP.a2023.0045. Epub 2023 Mar 5.

Individualized therapy in statin intolerance: the key to success.

Eur Heart J. 2023 Feb 14;44(7):544-546. doi: 10.1093/eurheartj/ehac556.

Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate?

Eur Heart J Open. 2022 Jun 7;2(4):oeac038. doi: 10.1093/ehjopen/oeac038. eCollection 2022 Jul.

Statin intolerance: time to stop letting it get in the way of treating patients.

Lancet. 2022 Sep 10;400(10355):791-793. doi: 10.1016/S0140-6736(22)01643-9. Epub 2022 Aug 29.

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).

J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1596-1622. doi: 10.1002/jcsm.12960. Epub 2022 Mar 10.

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.

Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18.

Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies ( = 355,591) and randomized controlled trials ( = 165,988).

Arch Med Sci. 2022 Jan 19;18(4):912-929. doi: 10.5114/aoms/145970. eCollection 2022.

Post-discharge and long-term follow-up after an acute coronary syndrome: International Collaborative Group of CNCF position paper.

Arch Med Sci. 2022 Jun 23;18(4):839-854. doi: 10.5114/aoms/150321. eCollection 2022.

Influence of lipid-lowering drugs on inflammation: what is yet to be done?

Arch Med Sci. 2021 Mar 20;18(4):855-869. doi: 10.5114/aoms/133936. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献